| 2905.41.00 | 00 | 2-Ethyl-2-(hydroxymethyl)propane-1,3-diol (Trimethylolpropane) | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P,SG) | 25% |
| 2917.39.04 | 00 | 1,2,4-Benzenetricarboxylic acid, 1,2-dianhydride (Trimellitic anhydride); Phthalic acid; and 4-Sulfo-1,8-naphthalic anhydride | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4¢/kg + 37% |
| 2920.90.50 | 10 | Trimethyl phosphite, triethyl phosphite, dimethyl phosphite and diethyl phosphite | kg | | | |
| 2921.11.00 | 00 | Methylamine, di- or trimethylamine and their salts | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P,SG) | 25% |
| 2921.49.10 | 00 | 4-Amino-2-stilbenesulfonic acid and its salts; p-Ethylaniline; 2,4,6-Trimethylaniline (Mesidine); 2,3-Xylidine; 2,4-Xylidine; 2,5-Xylidine; and 3,4-Xylidine | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4¢/kg + 48.5% |
| 2931.00.70 | 00 | N,N'-Bis(trimethylsilyl)urea; 3-(Hydroxymethylphosphinyl)-1-propanoic acid, 2-hydroxyethyl ester; and 2-Phosphonobutane-1,2,4-tricarboxylic acid and its salts | kg | Free | | 25% |
| 2933.33.00 | 00 | Alfentanil (INN), anileridine (INN), bezitramide (INN), bromazepam (INN), difenoxin (INN), diphenoxylate (INN), dipipanone (INN), fentanyl (INN), ketobemidone (INN), methylphenidate (INN), pentazocine (INN), pethidine (INN), pethidine (INN) intermediate A, phencyclidine (INN) (PCP), phenoperidine (INN), pipradrol (INN), piritramide (INN), propiram (INN) and trimeperidine (INN); salts thereof | kg | Free | | 15.4¢/kg + 149.5% |
| 2933.49.10 | 00 | Ethoxyquin (1,2-Dihydro-6-ethoxy-2,2,4- trimethylquinoline) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4¢/kg + 55% |
| 2933.52 | | Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: | | | | |
| 2933.59.22 | 00 | Nicarbazin; and Trimethoprim | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¢/kg + 46% |
| 2933.59.85 | 00 | 2-Amino-4-chloro-6-methoxypyrimidine; 2-Amino-4,6-dimethoxypyrimidine; and 6-Methyluracil | kg | Free | | 30.5% |
| 2933.99.08 | 00 | Acetoacetyl-5-aminobenzimidazolone; 3-(2H-Benzotriazol-2-yl)-5-(tert-butyl)-4- hydroxybenzene propanoic acid, C7-C9 branched or linear alkyl esters; 2-(2H-Benzotriazol-2-yl)-6-dodecyl-4- methyl phenol, in liquid form, branched and linear; and 1,3,3-Trimethyl-2-methyleneindoline | kg | Free | | 15.4¢/kg + 52% |
| 2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
| 2934.20.30 | 00 | 2-Amino-6-methoxybenzothiazole; 2-Amino-6-methylbenzothiazole; 6-Ethoxy-2-benzothiazolethiol; 3-Methylbenzothiazole-2-hydrazone; and Primuline base | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4¢/kg + 39.5% |
| 2935.00.13 | 00 | (5-[2-Chloro-4-(trifluoromethyl)phenoxy]-¢/(methylsulfonyl)-2-nitrobenzamide) (Fomesafen); N-(2,6-Dichloro-3-methylphenyl)-5-amino-1,3,4- triazole-2-sulfonamide; 2,4-Dichloro-5-sulfamoylbenzoic acid; N-Ethyl-o-toluenesulfonamide; N-Ethyl-p-toluenesulfonamide; 7-(Hexadecylsulfonylamino)-1H-indole; Methyl 5-{[(4,6-dimethoxy-2-pyrimidinyl)amino]- carbonylaminosulfonyl}-3-chloro-1-methyl-1H- pyrazole-4-carboxylate (Halosulfuron methyl); and Mixtures of ortho- and para-toluene sulfonamides | kg | Free | | 15.4¢/kg + 57.5% |
| 2936 | | Provitamins and vitamins, natural or reproduced by synthesis (including natural concentrates), derivatives thereof used primarily as vitamins, and intermixtures of the foregoing, whether or not in any solvent: | | | | |
| 2937 | | Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis; derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones: | | | | |
| 3004.40.00 | 20 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.40.00 | 60 | Medicaments primarily affecting the eyes, ears or respiratory system | kg | | | |
| 3004.90.91 | 65 | Preparations primarily affecting the electrolytic, caloric or water balance: | | | | |
| 3004.90.91 | 22 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.90.91 | 50 | Medicaments primarily affecting the digestive system: | | | | |
| 3824.90.22 | 00 | Consisting of polymers of 1,2-dihydro- 2,2,4-trimethylquinoline averaging less than 5 monomer units | kg | 6.5% | Free (A,AU,BH, CA,CL,E,IL,J,JO, K,MA,MX,P) 0.2¢/kg + 3.1% (SG) | 15.4¢/kg + 52% |
| 3901 | | Polymers of ethylene, in primary forms: | | | | |
| 3902 | | Polymers of propylene or of other olefins, in primary forms: | | | | |
Harmonized Tariff Schedule of the United States inquiry: 3203Ã
